Release Date: March 23, 2022
Expiration Date: March 23, 2023
Activity Overview
Much of the substantial morbidity, mortality, and cost associated with chronic gastrointestinal disorders, including irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), can be mitigated through the provision of quality care by a dedicated clinician. To maintain their high level of care, clinicians must remain up to date on advances in the field.
The Annual Live Medical Crossfire®: IBS and IBD conference is 1-day CME symposium designed to educate and empower clinicians who care for patients with IBS and IBD about emerging data and best practices for diagnosing and treating these disorders. It provides a unique opportunity for clinicians to learn from and interact with leading expert faculty to increase clinical knowledge, apply new data to practice, and ultimately improve patient outcomes.
This educational activity is an archive of the 3rd Annual Live Medical Crossfire®: IBS and IBD virtual conference held on February 19, 2022.
Target Audience
This educational activity is directed toward gastroenterologists and primary care physicians. Nurse practitioners, physician assistants, pharmacists, researchers, and other health care professionals involved in the treatment and management of IBS and IBD are also invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
• Develop an evidence-based plan for diagnosis of patients with suspected IBS and IBD
• Analyze efficacy and safety data for new and emerging treatments for IBS and IBD
• Review current treatment guidelines for providing optimal care to patients with IBS and IBD
• Implement management strategies for short-term and long-term management of IBD and IBS
William D. Chey, MD, FACG, AGAF, RFF
Nostrant Professor of Gastroenterology & Nutrition Sciences
Incoming Chief
Division of Gastroenterology
University of Michigan
Ann Arbor, MI
Disclosures: Grant/Research Support: Biomerica, Commonwealth Diagnostics International, QOL Medical, Urovant Sciences, Vibrant Therapeutics; Consultant: Biomerica, Ironwood Pharmaceuticals, QOL Medical, Urovant Sciences, Vibrant Therapeutics, Takeda, Salix Pharmaceuticals/Valeant Pharmaceuticals, Ritter Pharmaceuticals; Shareholder: Ritter Pharmaceuticals.
Bruce E. Sands, MD, MS
Dr Burrill B. Crohn Professor of Medicine
Chief, Dr Henry D. Janowitz Division of Gastroenterology
Mount Sinai Hospital
Chief, Division of Gastroenterology
Mount Sinai Health System
Director, Digestive Disease Institute
Icahn School of Medicine at Mount Sinai
New York, NY
Disclosures: Consultant: AbbVie, Abivax, Alimentiv, Amgen, Arena Pharmaceuticals, Artugen Therapeutics, AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Calibr, Celltrion Healthcare, ClostraBio, Entera Bio, Evommune, Galapagos, Genentech, Gossamer Bio, HMP Global, InDex Pharmaceuticals, Innovation Pharmaceuticals, Janssen, Kaleido Biosciences, Lilly, Merck & Co, Morphic Therapeutic, MRM Health, Pfizer, Progenity, Prometheus Biosciences, Q32 Bio, Sun Pharma, Takeda, Target RWE, Teva Pharmaceutical Industries, Theravance Biopharma, TLL Pharmaceutical, Ventyx Biosciences, Vivante Health. Shareholder: Ventyx Biosciences, Vivante Health.
Jessica R. Allegretti, MD, MPH, FACG
Director of Clinical Research
Director, Fecal Microbiota Transplant Program
Associate Director, Crohn’s and Colitis Center
Division of Gastroenterology, Hepatology and Endoscopy
Brigham and Women’s Hospital
Assistant Professor of Medicine, Harvard Medical School
Boston, MA
Disclosures: Grant/Research Support: Merck & Co; Consultant: Finch Therapeutics, Pfizer, Takeda, Janssen, Artugen Therapeutics, Servatus, Pandion Therapeutics, Iterative Scopes.
Lin Chang, MD
Vice Chief, Vatche and Tamar Manoukian Division of Digestive Diseases
Program Director, University of California (UCLA) GI Fellowship Program
Co-Director, G. Oppenheimer Center for Neurobiology of Stress and Resilience
David Geffen School of Medicine at UCLA
Los Angeles, CA
Disclosures: Grant/Research Support: Arena, AnX Robotica, Ironwood Pharmaceuticals; Consultant: Ironwood Pharmaceuticals, Immunic Therapeutics, Mauna Kea Technologies, Trellus Health; Shareholder: ModifyHealth, Trellus Health; Royalties: Rome Foundation.
Shanti L. Eswaran, MD
Clinical Associate Professor
University of Michigan
Ann Arbor, MI
Shanti L. Eswaran, MD has no relevant financial relationships with ineligible companies.
Kimberly Nicole Harer, MD, ScM
Clinical Lecturer
Gastroenterology, Internal Medicine
University of Michigan Health
Ann Arbor, MI
Kimberly Nicole Harer, MD, ScM has no relevant financial relationships with ineligible companies.
Vipul Jairath, MBChB, DPhil, MRCP, FRCPC
Professor of Medicine
Departments of Medicine, Epidemiology and Biostatistics
John and Susan McDonald Endowed Chair in Inflammatory Bowel Disease Clinical Research
Division of Gastroenterology
Western University & London Health Sciences Centre
London, ON, Canada
Disclosures: Grant/Research Support: Celgene/Bristol Myers Squibb, Pfizer, AbbVie, Boehringer Ingelheim, Eli Lilly and Company, Janssen, Takeda, Gilead Sciences, TiGenix; Consultant: AbbVie, Alimentiv Inc (formerly Robarts Clinical Trials Inc), Amgen, Applied Strategic, Arena Pharmaceuticals, Asahi Kasei Pharma, Asieris Pharmaceuticals, AstraZeneca, Celgene/Bristol Myers Squibb, Celltrion Healthcare, Eli Lilly and Company, Ferring Pharmaceuticals, F. Hoffmann-La Roche Ltd, Flagship Pioneering, Fresenius Kabi, Galapagos NV, Genentech, Gilead Sciences, GlaxoSmithKline, Janssen, Organon & Co (Merck), Mylan, Pandion Therapeutics, PENDOPHARM, Pfizer, Reistone Biopharma, Sandoz, Second Genome, Takeda, Teva Pharmaceuticals Industries, TopiVert Pharma, Ventyx Biosciences, Vividion Therapeutics.
Maia Kayal, MD, MS
Assistant Professor
The Susan and Leonard Feinstein Inflammatory Bowel Disease Center
Icahn School of Medicine at Mount Sinai
New York, NY
Maia Kayal, MD, MS has no relevant financial relationships with ineligible companies.
Gary R. Lichtenstein, MD
Professor of Medicine
Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania
Director, Center for Inflammatory Bowel Disease
Department of Medicine
Division of Gastroenterology
Philadelphia, PA
Disclosures: Grant/Research Support: Vindico Medical Education, University of Kentucky, Janssen Biotech, Ironwood Pharmaceuticals, Imedex, Chemed, Celgene, Bristol Myers Squibb, American Gastroenterological Association, Allergan; Consultant: AbbVie, American Regent, Bristol Meyers Squibb, Celgene, Eli Lilly and Company, Endo International, Ferrin Pharmaceuticals, Gilead Sciences, Janssen Biotech, MedEd Consultants, Merck & Co, Prometheus Biosciences, Morphic Therapeutic, Pfizer Pharmaceuticals, Prometheus Laboratories, Romark, Sandoz, Salix Pharmaceuticals/Valeant Pharmaceuticals, Shire Pharmaceuticals/Takeda Oncology, UCB, Virgo Pharmaceuticals. Author honorarium: Springer Science+ Business Media, Editor; SLACK, Inc, book royalty; Professional Communication, Clinical Management of Ulcerative Colitis; Eli Lilly and Company; Data Safety Monitoring Board; American College of Gastroenterology Associate Editor, American Journal of Gastroenterology.
Paul Moayyedi, BSc, MBChB, PhD, MPH, FRCP, FRCPC, AGAF, FACG, CAGF
Assistant Dean of Research
Audrey Campbell Chair of Ulcerative Colitis Research
McMaster University
Hamilton, ON, Canada
Paul Moayyedi, BSc, MBChB, PhD, MPH, FRCP, FRCPC, AGAF, FACG, CAGF has no relevant financial relationships with ineligible companies.
Mark Pimentel, MD, FRCP(C)
Executive Director, Medically Associated Science and Technology (MAST) Program
Head, Pimentel Laboratory
Cedars-Sinai Medical Center
Los Angeles, California
Disclosures: Grant/Research Support: Bausch Health, Synthetic Biologics, 9 Meters Biopharma; Consultant: 9 Meters Biopharma, Synthetic Biologics, Ferring Pharmaceuticals, Bausch Health, Progenity, Gemelli Biotech, Aytu BioPharma; Shareholder: Gemelli Biotech, Synthetic Biologics.
Mark S. Riddle, MD, DrPH
Professor, Internal Medicine
Associate Dean for Clinical Research
University of Nevada, Reno School of Medicine
Reno, NV
Mark S. Riddle, MD, DrPH has no relevant financial relationships with ineligible companies.
Sumona Saha, MD, MS
Associate Professor of Medicine
Director of IBD, UW Health
University of Wisconsin School of Medicine and Public Health
Madison, WI
Disclosures: Consultant: AbbVie, Eli Lilly and Company, Synesis Nutrition.
Jack Satsangi, DPhil, FRCP
Lee Placito Professor of Gastroenterology, Nuffield Department of Medicine
University of Oxford
Oxford, United Kingdom
Jack Satsangi, DPhil, FRCP has no relevant financial relationships with ineligible companies.
Gregory S. Sayuk, MD, MPH
Professor of Medicine and Psychiatry
Division of Gastroenterology
Washington University School of Medicine
St Louis, MO
Disclosures: Grant/Research Support: Allakos; Consultant: Ironwood Pharmaceuticals, AbbVie, Salix Pharmaceuticals, Alnylam Pharmaceuticals, GI Health Foundation, Rome Foundation; Speaker’s Bureau: Ironwood Pharmaceuticals, AbbVie, Salix Pharmaceuticals, Alnylam Pharmaceuticals.
Siddharth Singh, MD, MS
Director, IBD Center
Associate Professor of Medicine
Division of Gastroenterology
University of California San Diego
La Jolla, CA
Disclosures: Grant/Research Support: Janssen, AbbVie, Pfizer; Ad Hoc Grant Review: Pfizer.
Serre-Yu Wong, MD, PhD
Instructor
The Henry D. Janowitz Division of Gastroenterology
Department of Medicine
Icahn School of Medicine at Mount Sinai
New York, NY
Disclosures: Grant/Research Support: The Leona M. and Harry B. Helmsley Charitable Trust.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
